Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2005 1
2008 1
2011 6
2012 1
2013 1
2014 1
2015 2
2016 1
2017 2
2018 1
2019 3
2020 3
2021 6
2022 5
2023 4
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

35 results

Results by year

Filters applied: . Clear all
Page 1
Safety and Efficacy of Immune Checkpoint Inhibitors in Patients With Cancer and Preexisting Autoimmune Disease: A Nationwide, Multicenter Cohort Study.
Tison A, Quéré G, Misery L, Funck-Brentano E, Danlos FX, Routier E, Robert C, Loriot Y, Lambotte O, Bonniaud B, Scalbert C, Maanaoui S, Lesimple T, Martinez S, Marcq M, Chouaid C, Dubos C, Brunet-Possenti F, Stavris C, Chiche L, Beneton N, Mansard S, Guisier F, Doubre H, Skowron F, Aubin F, Zehou O, Roge C, Lambert M, Pham-Ledard A, Beylot-Barry M, Veillon R, Kramkimel N, Giacchero D, De Quatrebarbes J, Michel C, Auliac JB, Gonzales G, Decroisette C, Le Garff G, Carpiuc I, Vallerand H, Nowak E, Cornec D, Kostine M; Groupe de Cancérologie Cutanée, Groupe Français de Pneumo-Cancérologie, and Club Rhumatismes et Inflammations. Tison A, et al. Among authors: mansard s. Arthritis Rheumatol. 2019 Dec;71(12):2100-2111. doi: 10.1002/art.41068. Epub 2019 Oct 21. Arthritis Rheumatol. 2019. PMID: 31379105
First-Line, Fixed-Duration Nivolumab Plus Ipilimumab Followed by Nivolumab in Clinically Diverse Patient Populations With Unresectable Stage III or IV Melanoma: CheckMate 401.
Dummer R, Corrie P, Gutzmer R, Meniawy TM, Del Vecchio M, Lebbé C, Guida M, Dutriaux C, Dreno B, Meyer N, Ferrucci PF, Dalle S, Khattak MA, Grob JJ, Briscoe K, Larkin J, Mansard S, Lesimple T, Guidoboni M, Sabatini S, Richtig E, Herbst R, Lobo M, Askelson M, Ascierto PA, Maio M. Dummer R, et al. Among authors: mansard s. J Clin Oncol. 2023 Aug 10;41(23):3917-3929. doi: 10.1200/JCO.22.02199. Epub 2023 Jun 12. J Clin Oncol. 2023. PMID: 37307514 Clinical Trial.
Response to BRAF and MEK Inhibitors in BRAF Thr599dup-Mutated Melanoma.
Oberlé M, Jamme P, Mansard S, Machet L, Hervieu A, Kramkimel N, Greliak A, Jarrousse AS, Derangère V, Dudoignon D, Descarpentries C, Mortier L. Oberlé M, et al. Among authors: mansard s. JCO Precis Oncol. 2022 Mar;6:e2100417. doi: 10.1200/PO.21.00417. JCO Precis Oncol. 2022. PMID: 35319964 No abstract available.
Clostridium difficile infection and immune checkpoint inhibitor-induced colitis in melanoma: 18 cases and a review of the literature.
Vuillamy C, Arnault JP, Fumery M, Mortier L, Monestier S, Mansard S, Bens G, Duval-Modeste AB, Funck-Brentano E, Jeudy G, Machet L, Chaby G, Dadban A, Lok C; Groupe de Cancérologie Cutanée de la Société Française de Dermatologie. Vuillamy C, et al. Among authors: mansard s. Melanoma Res. 2023 Jun 1;33(3):192-198. doi: 10.1097/CMR.0000000000000878. Epub 2023 Mar 27. Melanoma Res. 2023. PMID: 36995276 Free PMC article. Review.
Vismodegib efficacy in unresectable trichoblastic carcinoma: A multicenter study of 16 cases.
Duplaine A, Beylot-Barry M, Mansard S, Arnault JP, Grob JJ, Maillard H, Saiag P, Poulalhon N, Cribier B, Mortier L, Battistella M, Jouary T. Duplaine A, et al. Among authors: mansard s. J Am Acad Dermatol. 2022 Jun;86(6):1365-1366. doi: 10.1016/j.jaad.2021.05.024. Epub 2021 May 27. J Am Acad Dermatol. 2022. PMID: 34052337 No abstract available.
Phase I study of [131I] ICF01012, a targeted radionuclide therapy, in metastatic melanoma: MELRIV-1 protocol.
Thivat E, Rouanet J, Auzeloux P, Sas N, Jouberton E, Levesque S, Billoux T, Mansard S, Molnar I, Chanchou M, Fois G, Maigne L, Chezal JM, Miot-Noirault E, D'Incan M, Durando X, Cachin F. Thivat E, et al. Among authors: mansard s. BMC Cancer. 2022 Apr 15;22(1):417. doi: 10.1186/s12885-022-09495-3. BMC Cancer. 2022. PMID: 35428211 Free PMC article.
Tetraspanin8 expression predicts an increased metastatic risk and is associated with cancer-related death in human cutaneous melanoma.
Berthier-Vergnes O, Barbollat-Boutrand L, Pommier RM, de la Fouchardière A, Combemale P, Grimont M, Lopez-Ramirez N, Caramel J, Dalle S, Perrot JL, Gaudy-Marqueste C, Macagno N, Mansard S, Bouquet F, Masse I. Berthier-Vergnes O, et al. Among authors: mansard s. Mol Cancer. 2021 Oct 2;20(1):127. doi: 10.1186/s12943-021-01429-0. Mol Cancer. 2021. PMID: 34600553 Free PMC article. No abstract available.
Effectiveness and safety of nivolumab in patients with advanced melanoma: A multicenter, observational study.
Monestier S, Dalle S, Mortier L, Dutriaux C, Dalac-Rat S, Meyer N, Leccia MT, Mansard S, Montaudié H, Saiag P, Combemale P, Guillot B, Skowron F, Duval Modeste AB, Bénéton N, Hainaut E, Robert C, Arnault JP, Le Corre Y, Jouary T, Ameur N, Varey E, Khammari A, Dréno B; RIC-Mel network. Monestier S, et al. Among authors: mansard s. Int J Cancer. 2021 Jun 1;148(11):2789-2798. doi: 10.1002/ijc.33467. Epub 2021 Feb 19. Int J Cancer. 2021. PMID: 33428772 Free article. Clinical Trial.
An open label, non-randomised, phase IIIb study of trametinib in combination with dabrafenib in patients with unresectable (stage III) or distant metastatic (stage IV) BRAF V600-mutant melanoma: A subgroup analysis of patients with brain metastases.
Dutriaux C, Robert C, Grob JJ, Mortier L, Dereure O, Lebbe C, Mansard S, Grange F, Neidhardt EM, Lesimple T, Machet L, Bedane C, Maillard H, Dalac-Rat S, Nardin C, Szenik A, Denden A, Saiag P. Dutriaux C, et al. Among authors: mansard s. Eur J Cancer. 2022 Nov;175:254-262. doi: 10.1016/j.ejca.2022.07.035. Epub 2022 Sep 25. Eur J Cancer. 2022. PMID: 36170791 Free article. Clinical Trial.
35 results